Safety, efficacy, PK, PD of dosing QBW251 in cystic fibrosis patients

• Research type

  Research Study

• Full title

  "A randomized, double blind placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of single and multiple ascending doses of QBW251 in healthy subjects and multiple doses in cystic fibrosis patients"

• IRAS ID

  143148

• Contact name

  J. Stuart Elborn

• Contact email

  s.elborn@qub.ac.uk

• Sponsor organisation

  Novartis Pharmaceuticals Inc

• Eudract number

  2011-005085-37

• REC name

  HSC REC A

• REC reference

  14/NI/0058

• Date of REC Opinion

  15 May 2014

• REC opinion

  Further Information Favourable Opinion